CSL accuses ex-exec, now at Pharming, of stealing trade secretsCSL Behring has filed a lawsuit against a former employee, claiming he stole sensitive information with the intention Share XCSL accuses ex-exec, now at Pharming, of stealing trade secretshttps://pharmaphorum.com/news/csl-accuses-ex-exec-now-at-pharming-of-stealing-trade-secrets/
UK’s Enterprise gets £5.7m backing for ‘universal’ cystic fibrosis drugEnterprise Therapeutics has been awarded a block of funding from the Cystic Fibrosis Foundation to take a new, Share XUK’s Enterprise gets £5.7m backing for ‘universal’ cystic fibrosis drughttps://pharmaphorum.com/news/uks-enterprise-gets-5-7m-backing-for-universal-cystic-fibrosis-drug/
Pfizer’s Xeljanz follow-up abrocitinib gathers momentumPfizer has reported new data with abrocitinib, a follow-up to its JAK inhibitor Xeljanz, which is facing increased Share XPfizer’s Xeljanz follow-up abrocitinib gathers momentumhttps://pharmaphorum.com/news/pfizers-xeljanz-follow-up-abrocitinib-gathers-momentum/
Reata rockets on data for Nrf2 drug reacquired from AbbVieReata Pharma has reported positive clinical results with one of its Nrf2 activators for mitochondrial diseases, just days Share XReata rockets on data for Nrf2 drug reacquired from AbbViehttps://pharmaphorum.com/news/reata-rockets-on-data-for-nrf2-drug-reacquired-from-abbvie/
Still too little progress on antibiotic resistance, says O’Neill report updateThe O’Neill report on antimicrobial resistance in 2016 generated headlines around the world warning that once-trivial infections may Share XStill too little progress on antibiotic resistance, says O’Neill report updatehttps://pharmaphorum.com/news/still-too-little-progress-on-antibiotic-resistance-says-oneill-report-update/
UCB sets sights on rare diseases giant Alexion with Ra Pharma acquisitionUCB is to buy US biotech Ra Pharma in a deal worth around $2.1 billion, adding a late-stage Share XUCB sets sights on rare diseases giant Alexion with Ra Pharma acquisitionhttps://pharmaphorum.com/news/ucb-takes-on-rare-diseases-giant-alexion-with-ra-pharma-acquisition/
Novo Nordisk builds in haemophilia with Bluebird Bio gene editing dealAnxious not to be left behind in the haemophilia market, Novo Nordisk has forged an alliance with Bluebird Share XNovo Nordisk builds in haemophilia with Bluebird Bio gene editing dealhttps://pharmaphorum.com/news/novo-nordisk-builds-in-haemophilia-with-bluebird-bio-gene-editing-deal/
Pfizer inks deal with Ionis and Akcea for potential blockbuster diabetes and NASH drugPfizer has signed a deal with Ionis’ affiliate Akcea Therapeutics, to develop a potential blockbuster antisense therapy to Share XPfizer inks deal with Ionis and Akcea for potential blockbuster diabetes and NASH drughttps://pharmaphorum.com/news/pfizer-inks-deal-with-ionis-and-akcea-for-potential-blockbuster-diabetes-and-nash-drug/
Sarepta rebounds on data for limb-girdle muscular dystrophy gene therapyShares in Sarepta spiked on positive data for its gene therapy for a form of muscular dystrophy, after Share XSarepta rebounds on data for limb-girdle muscular dystrophy gene therapyhttps://pharmaphorum.com/news/sarepta-rebounds-on-data-for-limb-girdle-muscular-dystrophy-gene-therapy/
After Alzheimer’s trial woes, Biogen’s R&D chief quits to head up biotech VCMichael Ehlers is to quit as head of Biogen’s troubled R&D outfit, taking a role as chief executive Share XAfter Alzheimer’s trial woes, Biogen’s R&D chief quits to head up biotech VChttps://pharmaphorum.com/news/after-alzheimers-trial-woes-biogens-rd-chief-quits-to-head-up-biotech-vc/
European regulators grant fast path to market for Calliditas’ rare kidney disease drugEuropean regulators have granted a fast path to market for Calliditas Therapeutics’ potential rare kidney disease drug, Nefecon, Share XEuropean regulators grant fast path to market for Calliditas’ rare kidney disease drughttps://pharmaphorum.com/news/european-grant-fast-path-to-market-for-calliditas-rare-kidney-disease-drug/
Novartis announces positive results from asthma combinationsNovartis has announced positive results from trials testing its daily fixed dose treatment two-drug combination for people with Share XNovartis announces positive results from asthma combinationshttps://pharmaphorum.com/news/novartis-announces-positive-results-from-asthma-combination-therapies/
ESMO 2019 – Amgen’s KRAS drug finds colorectal cancer a challengeAmgen’s KRAS inhibitor AMG 510 has shown little effect in colorectal cancer patients, according to new data reported Share XESMO 2019 – Amgen’s KRAS drug finds colorectal cancer a challengehttps://pharmaphorum.com/news/esmo-2019-amgens-kras-drug-finds-colorectal-cancer-a-challenge/
Evotec announces potential $850m R&D partnership with TakedaGermany’s Evotec has announced another high-profile R&D partnership with big pharma, beginning a multi-year R&D partnership with Takeda, Share XEvotec announces potential $850m R&D partnership with Takedahttps://pharmaphorum.com/news/evotec-announces-potential-850m-rd-partnership-with-takeda/
Brexit could freeze UK out of EU rare disease research, says patient groupThe UK risks being frozen out of cutting-edge European research into rare diseases after Brexit, a patient organisation Share XBrexit could freeze UK out of EU rare disease research, says patient grouphttps://pharmaphorum.com/news/brexit-could-freeze-uk-out-of-eu-rare-disease-research-says-patient-group/
bluebird presents long-term data from CALD gene therapybluebird bio has produced updated data from its gene therapy for the rare genetic neurological disease cerebral adrenoleukodystrophy Share Xbluebird presents long-term data from CALD gene therapyhttps://pharmaphorum.com/news/bluebird-presents-long-term-data-from-cald-gene-therapy/
Novartis points to Zolgensma long-term benefits amid data scandalNovartis has new data in hand for spinal muscular atrophy (SMA) gene therapy Zolgensma that it hopes will Share XNovartis points to Zolgensma long-term benefits amid data scandalhttps://pharmaphorum.com/news/novartis-points-to-zolgensmas-long-term-benefits-amid-data-scandal/
Roche’s Gazyva wins Breakthrough Therapy status for lupus nephritisRoche’s Gazyva has won Breakthrough Therapy status for its potential new use in the autoimmune disease lupus nephritis, Share XRoche’s Gazyva wins Breakthrough Therapy status for lupus nephritishttps://pharmaphorum.com/news/roches-gazyva-wins-breakthrough-therapy-status-for-lupus-nephritis/
